Testing NF-κB-based therapy in hemiparkinsonian monkeys.

Area of Science:

• Neuroscience
• Neurodegenerative Disorders
• Pharmacology

Background:

• Parkinson's disease (PD) is a prevalent neurodegenerative disorder impacting motor control, with no current cure.
• Neuroinflammation, involving the transcription factor NF-κB (nuclear factor kappa B), is implicated in PD pathogenesis.
• The primate model offers valuable insights into human PD.

Purpose of the Study:

• To investigate the neuroprotective potential of a peptide targeting the NEMO-binding domain (NBD) of IKK (IκB kinase) in a primate model of PD.
• To evaluate the efficacy of this peptide in mitigating neuroinflammation and dopaminergic neuron loss.

Main Methods:

• Hemiparkinsonian monkeys were induced using MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).
• Activation of NF-κB in the substantia nigra was assessed.
• Intramuscular administration of wild-type NBD (wtNBD) peptide or mutated NBD peptide was performed.
• Neuroprotection, neurotransmitter levels, and motor function were evaluated.

Main Results:

• NF-κB activation was confirmed in the substantia nigra of MPTP-intoxicated monkeys.
• wtNBD peptide administration significantly reduced NF-κB activation and inducible nitric oxide synthase expression.
• The treatment protected the nigrostriatal pathway and neurotransmitters, leading to improved motor function.
• Mutated NBD peptide did not produce these beneficial effects, confirming specificity.

Conclusions:

• The NBD peptide effectively inhibits NF-κB-driven neuroinflammation in a primate model of PD.
• This peptide demonstrates neuroprotective effects and functional recovery, highlighting its therapeutic potential.
• NF-κB-targeted therapies represent a promising strategy for future clinical translation in Parkinson's disease treatment.